Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
J Natl Compr Canc Netw
January 2025
National Comprehensive Cancer Network.
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence.
View Article and Find Full Text PDFThe landscape of drug sensitivity and resistance in sarcoma.
Cell Stem Cell
October 2024
Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address:
Article Synopsis
- - Sarcomas are rare tumors with over 100 subtypes, making it challenging to find effective therapies; there's a need for personalized treatment approaches to enhance patient outcomes.
- - Patient-derived tumor organoids (PDTOs) were used to study drug resistance and sensitivity in sarcoma, analyzing 194 specimens from 126 patients across 24 subtypes.
- - The research developed a high-throughput screening method that provided results quickly and showed that drug sensitivity linked to tumor characteristics; 59% of samples matched with at least one effective FDA-approved treatment.
How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer.
Cancers (Basel)
August 2024
Department of Thoracic and Abdominal Tumors and Clinical Pharmacology, National Institute of Oncology, 1122 Budapest, Hungary.
Background: The use of the Oncotype DX test reduces the rate of adjuvant chemotherapy recommendations. Few in-depth analyses have been performed on this decision-making process.
Methods: We retrospectively analyzed patient data based on available Oncotype DX test results (RS) irrespective of nodal status at a single center.
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Ann Oncol
December 2024
Institut Gustave Roussy, Villejuif, France.
Article Synopsis
- A study called IMADGIST assessed whether extending adjuvant imatinib treatment for an additional three years (totaling six years) improved disease-free survival in patients with high-risk localized gastrointestinal stromal tumors (GIST) who had already received three years of treatment after surgery.
- Conducted across 14 centers, the trial included 136 patients with varied risks of tumor recurrence, finding that those treated for six years had significantly better disease-free survival compared to those who stopped after three years.
- Although there was no significant difference in overall survival, time to imatinib resistance, or quality of life between the two groups, the results suggest that extending treatment can effectively lower relapse rates with
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
NPJ Precis Oncol
July 2024
Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!